Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )
ClinicalTrials.gov Identifier:
NCT00942799
First received: July 17, 2009
Last updated: March 17, 2014
Last verified: March 2014
  Purpose

This is a Phase I, open-label, multicenter, dose-escalation study designed to assess the safety and tolerability of Genz-644282, administered as an intravenous (IV) infusion, to patients with advanced malignant solid tumors. Each 28 day cycle of treatment will consist of 3 consecutive weeks of treatment every 28 days(i.e., treatment will be administered on Days 1, 8, and 15 every 28 days). Each 21 day cycle of treatment will consist of 2 consecutive weeks of treatment every 21 days(i.e., treatment will be administered on Days 1 and 8 every 21 days). Treatment with Genz-644282 will continue until disease progression or unacceptable toxicity is observed. Approximately 110 patients will be enrolled in this study. Patients will be enrolled in escalating dose cohorts until the Maximum Tolerated Doses (MTDs) for the 2 dosing schedules are established. To further evaluate safety, approximately 40 additional patients with advanced malignant solid tumors will be enrolled and treated at the MTDs (20 for each dosing schedule) during an expansion phase.


Condition Intervention Phase
Solid Tumors
Drug: Genz-644282 (28-day dosing schedule)
Drug: Genz-644282 (21-day dosing schedule)
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Advanced Malignant Solid Tumors

Resource links provided by NLM:


Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Determine the Maximum Tolerated Doses for the 28-day and 21-day dosing schedules [ Time Frame: 24 Months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Determine the recommended Phase 2 doses for the 28-day and 21-day dosing schedules [ Time Frame: 36 Months ] [ Designated as safety issue: Yes ]
  • Establish the pharmacokinetic (PK) profile through calculation of area under the curve of blood and urine concentrations. [ Time Frame: 36 Months ] [ Designated as safety issue: No ]
  • Pharmacokinetics (PK) as measured by maximal observed concentration (Cmax) [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Pharmacokinetics (PK) as measured by time to maximal observed concentration (Tmax) [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Pharmacokinetics (PK) as measured by half-life (T1/2) [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Pharmacokinetics (PK) as measured by the amount and fraction of drug excreted in urine [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Assess evidence of antitumor activity [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Evaluate ongoing benefit as determined by the investigator and defined as an improvement in performance status [ Time Frame: 36 months ] [ Designated as safety issue: No ]

Enrollment: 87
Study Start Date: July 2009
Study Completion Date: January 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Study Drug: Genz-644282 (28-day dosing schedule)
Genz-644282 (Each cohort will be based on dose-escalation)
Drug: Genz-644282 (28-day dosing schedule)
Genz-644282 will be administered as a 60-minute IV infusion. The initial dose of Genz-644282 will be 0.5 mg/m2 and will be administered once weekly for 3 consecutive weeks on Day 1, Day 8, and Day 15 of the 28 day cycle. Each 28-day period will represent one treatment cycle. Study drug will continue to be given until disease progression or unacceptable toxicity is observed.
Experimental: Study Drug: Genz-644282 (21-day dosing schedule)
Genz-644282 (Each cohort will be based on dose-escalation)
Drug: Genz-644282 (21-day dosing schedule)
The starting dose of Genz-644282 for the 21-day schedule will be prescriptive and will be based on review of available safety data from the 28-day dosing schedule by the Investigator and Sponsor. Patients will receive Genz-644282 once-weekly for 2 consecutive weeks on Day 1 and Day 8 of a 21 day cycle. Each 21-day period will represent 1 treatment cycle. Patients enrolled in subsequent cohorts will receive higher doses until the MTD is established.

Detailed Description:

This is a Phase I, open-label, multicenter, dose-escalation study designed to assess the safety and tolerability of Genz-644282, administered as an IV infusion, to patients with advanced malignant solid tumors. Drug will be administered as a 60-minute IV infusion on days 1, 8, and 15 of the 28 day treatment cycle, or on days 1 and 8 of the 21 day treatment cycle.

Treatment with Genz-644282 will continue until disease progression or unacceptable toxicity is observed. Patients will be enrolled in escalating dose cohorts until the Maximum Tolerated Doses (MTDs) are established.

Safety will be evaluated throughout the study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed written informed consent
  • Patients enrolled in dose-escalation phase: Histologically or cytologically confirmed advanced malignant solid tumor for which no standard therapeutic option exists.
  • For the disease indications evaluated in the expansion phase, the following criteria must be met:

    1. Have one of the following histologically or cytologically confirmed advanced malignant solid tumors for which no standard therapeutic option exists:

      • Colorectal cancer (prior systemic regimen must have included ≥1 of the following: fluoropyrimidine or oxaliplatin);
      • Squamous Non-small cell lung cancer or small cell lung cancer (prior systemic regimen must have included ≥1 of the following: cis-platinum or carbo platinum);
      • Pancreatic cancer (prior systemic regimen must have included gemcitabine);
      • Breast cancer (prior systemic regimen must have included ≥1 of the following: taxane, anthracycline, or fluoropyrimidine)
    2. Received no more than 4 prior systemic therapy regimens for their malignancy
    3. Experienced progression or intolerance to their immediate prior systemic therapy regimen.
  • Evaluable or measurable disease.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Life expectancy of at least 12 weeks.
  • Adequate organ and hematologic function.
  • Prior chemotherapy, major surgery, or irradiation must have been completed at least 3 weeks prior to starting treatment with study drug, with the exception of mitomycin-C or nitrosoureas, which should be completed at least 6 weeks prior. Additionally, patients must have recovered to ≤ Grade 1 toxicities incurred as a result of the previous therapy, with the exception of nail dystrophy, alopecia, or local radiation therapy induced adverse events (e.g., impotence or incontinence). A patient who has received radiation to < 5% of their total bone marrow volume and who has had 2 weeks of rest may be considered for study entry after discussion with the Sponsor
  • Hormone treatment must have been completed > 2 weeks prior to receiving study drug.
  • Prostate cancer patients who are chemically castrated with hormonal therapy (e.g., luteinizing hormone-releasing hormone agonists) will be allowed to enter the study. However, doses and schedules of such treatments must be maintained throughout the trial and all major toxicities must have resolved to ≤ Grade 1 prior to study entry.
  • Concomitant stable treatment with bisphosphonates is allowed, unless dose requires readjustments or discontinuation.
  • Ability to comply with study procedures and follow-up examinations.
  • Male and female patients must agree to use an effective barrier means of birth control (i.e., latex condom, diaphragm, cervical cap, etc.) throughout the entire duration of the study and for at least 3 months after last dose of study drug.
  • Male patients must agree to not donate sperm throughout the study and for at least 3 months following the last dose of study drug.

Exclusion Criteria:

  • Received previous treatment with or have a known hypersensitivity to Genz-644282 or to any of its components.
  • Received radiotherapy to the only site of measurable disease, unless the tumor at this site continues to increase in size after the patient has completed radiotherapy treatment.
  • Used any investigational agent, other than anti-cancer chemotherapy, during the 4 weeks prior to the first dose of Genz-644282.
  • Have psychiatric disorder(s) that would interfere with consent, study participation, or follow up (with the possible exception of incompetence as defined by New Jersey for the purposes of participation in clinical trials in the state of New Jersey).
  • Have uncontrolled congestive heart failure or angina, a history of myocardial infarction within 6 months prior to study enrollment, or a cardiac functional capacity Class III or IV, as defined by the New York Heart Association Classification.
  • Have a resting QT with Bazett's correction (QTcB) interval of > 460 msec, calculated as the average of at least 2 of the longest QT intervals measured on 12-lead recordings made prior to dosing with Genz-644282.
  • Have a systemic fungal, bacterial, viral, or other infection that is not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement) despite appropriate antibiotics or other treatment.
  • Have any other severe concurrent disease or a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo chemotherapy.
  • A known diagnosis of human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS) or viral hepatitis B or C.
  • Presence of ≥ Grade 2 peripheral neuropathy.
  • Pregnant or lactating women, due to the unknown effects of Genz-644282 on the developing fetus or newborn infant.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00942799

Locations
United States, Arizona
TGen Clinical Research Services at Scottsdale Healthcare
Scottsdale, Arizona, United States
United States, Florida
Moffitt Cancer Center
Tampa, Florida, United States
United States, Michigan
Wayne State University, Division of Hematology/Oncology, Karmanos Cancer Institute
Detroit, Michigan, United States
United States, New Jersey
Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Sponsors and Collaborators
Genzyme, a Sanofi Company
Investigators
Study Director: Medical Monitor Genzyme, a Sanofi Company
  More Information

No publications provided

Responsible Party: Sanofi ( Genzyme, a Sanofi Company )
ClinicalTrials.gov Identifier: NCT00942799     History of Changes
Other Study ID Numbers: GZ28200108
Study First Received: July 17, 2009
Last Updated: March 17, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Sanofi:
Genz-644282
Topoisomerase I inhibitors
Top1
solid tumors
dose-escalation
pharmacokinetic (PK)
MTD (Maximum Tolerated Dose)
oncology
cancer

Additional relevant MeSH terms:
Neoplasms

ClinicalTrials.gov processed this record on September 18, 2014